Phase 3 Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 years or older
- People who are able and willing to give their formal consent to take part in the study
- People who have been diagnosed with brain metastases (cancer that has spread to the brain) and have at least one visible affected area showing up on a brain MRI scan with contrast dye
- People who have received radiation therapy to the brain at some point in the last 2 years
- People who are currently receiving, or have received in the past 6 months, another type of systemic treatment alongside radiation — such as immunotherapy, targeted therapy, or chemotherapy
- People whose most recent standard MRI scan has raised uncertainty about whether changes in the brain represent cancer returning or are the result of previous treatment — this concern may have been raised by a radiologist, a specialist team, or a treating doctor based on symptoms or changing exam findings
- People who are able to lie still for 30 to 60 minutes during the imaging procedure
- People who are willing and able to undergo a PET/MRI or PET/CT scan
- People who take a mild anti-anxiety tablet by mouth before imaging may still be considered eligible, provided that: the prescription for that medication belongs to the patient themselves; consent to participate in the study is given before taking the medication; and the patient attends the visit with a driver
Who may not be able to join:
- People who are unable or unwilling to give formal consent to participate
- People who are pregnant
- People who have a medical reason preventing them from undergoing a PET/MRI or PET/CT scan
- People with a known allergy to the imaging agent used in this study, called 18F-Fluciclovine, or any of its ingredients
- People who would need intravenous (IV) sedation in order to undergo imaging
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Michael Veronesi, MD, PhD, University of Wisconsin, Madison
Phone: 608-282-8349
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Amino acid uptake into tumor tissue
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.